EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Daiichinkyo Co's Enterprise Value is $54,646 Mil.
Daiichinkyo Co's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2024 was $3,312 Mil. Therefore, Daiichinkyo Co's EV-to-FCF for today is 16.50.
The historical rank and industry rank for Daiichinkyo Co's EV-to-FCF or its related term are showing as below:
DSNKY'
s EV-to-FCF Range Over the Past 10 Years
Min: -498.58 Med: 32.11 Max: 537.72
Current: 17.81
During the past 13 years, the highest EV-to-FCF of Daiichinkyo Co was 537.72. The lowest was -498.58. And the median was 32.11.
DSNKY's EV-to-FCF is ranked better than 60.67% of 511
companies
in the Drug Manufacturers industry
Industry Median: 22.05
vs DSNKY: 17.81
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The historical data trend for Daiichinkyo Co's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Daiichinkyo Co's EV-to-FCF
For the Drug Manufacturers - General subindustry, Daiichinkyo Co's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Daiichinkyo Co's EV-to-FCF Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Daiichinkyo Co's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Daiichinkyo Co's EV-to-FCF falls into.
Daiichinkyo Co's current Enterprise Value is $54,646 Mil.
Daiichinkyo Co's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $3,312 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Daiichinkyo Co (OTCPK:DSNKY) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Daiichinkyo Co's PE Ratio for today is calculated as:
Daiichinkyo Co's share price for today is $32.20.
Daiichinkyo Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.721.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Daiichinkyo Co EV-to-FCF Related Terms
Thank you for viewing the detailed overview of Daiichinkyo Co's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.
Daiichinkyo Co (Daiichinkyo Co) Business Description
Daiichi Sankyo was established by the merger of Daiichi Pharmaceuticals and Sankyo in 2005. As of 2021, approximately half of revenue comes from its Japan businesses, which will shrink in the future as the company expands its global footprint. Its primary growth driver is its leading platform of antibody drug conjugates. Its three lead ADCs are Enhertu (HER2), Dato-DXd (TROP2), I-DXd (B7-H3), HER3-DXd (HER3), and R-DXd (CDH6). Enhertu entered the clinic in 2015 and received its first U.S approval in December 2019 for third-line late-stage HER2-positive breast cancer. It is also approved for HER2-positive stomach cancers and HER2 mutant non-small cell lung cancer.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
DSNKY has been successfully added to your 